Lipigon Pharmaceuticals announces that the last patient in the company's clinical phase II study of Lipisense has completed the three-month follow-up. The study includes 23 patients with elevated blood lipid levels and evaluates safety and tolerability. Preliminary study data are expected to be presented before the end of 2025/2026. Lipisense is an RNA drug candidate that increases the body's breakdown of blood fats by removing the protein ANGPTL-4.
|
Published October 15, 2025
Lipigon completes three-month follow-up in phase II study
Text:
News Desk [email protected]
Notes
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
Merck acquires Cidara for approximately USD 9,2 billion
Coegin Pharma launches first Follicopeptide product
Ascelia Pharma receives FDA acceptance for Orviglance application
Diamyd Medical passes safety review ahead of Phase III readout
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account